Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all

NCT01083368 2019-08-21

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Phase 1/2 Completed

22 enrolled 15 charts

Prostatic Neoplasms